Injectafer, made by Daiichi Sankyo, is a ferric carboxymaltose injection treatment for iron deficiency in adult patients with heart failure to improve exercise capacity, according to a June 5 company news release. It has already been approved in 86 countries since 2007 and is the most extensively studied IV iron treatment.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
